NCT02322645已完成1 期
An Open Label, Balanced, Randomized, Two-Treatment, Two Period, Two-Sequence, Single Dose, Crossover, Oral Bioequivalence Study Of Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited, and 'LUNESTA' Tablets 3 mg, Mfg For Sepracor Inc. USA In Healthy Adult Human Subjects Under Fasting Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Area under curve
研究概览
简要总结
This is an open-label, randomized, two-period, two-treatment, two-sequence, balanced, single dose, crossover, oral bioequivalence study in healthy, adult, human subjects under fasting conditions.
详细描述
An open label, balanced, randomized, two-treatment, two-period, two-sequence,single dose, crossover, oral bioequivalence study of Eszopiclone tablets 3 mg of Dr. Reddy's Laboratories limited, and 'LUNESTA' tablets 3 mg Mfg for Sepracor Inc. USA in healthy adult human subjects under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subjects should be healthy human between 18 and 45 years.
- •The subjects should be screened within 21 days prior to the administration of first dose of the study drug.
- •The subjects should have a BMI between 18.5 and 24.9 weight in kg/ height2 in meter.
- •The subjects should be able to communicate effectively with study personnel.
- •The subjects should be able to give written informed consent to participate in the study.
- •If subject is a female volunteer and
- •Is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence or
- •Is postmenopausal for at least 1 year or
- •Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).
排除标准
- •The subjects who have a history of allergic responses to Eszopiclone or other related drugs.
- •The subjects who have significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, ECG and X-ray recordings.
- •The subjects who have any disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •The subjects who have a history or presence of bronchial asthma.
- •Use of enzyme-modification drugs within 30 days prior to receiving the first dose of study medication.
- •History of drug dependence, recent history of alcoholism or of moderate alcohol use.
- •The subjects who are smokers who smoke more than or equal to 10 cigarettes per day or more than or equal to 20 biddies per day or those who cannot refrain from smoking during study period.
- •The subjects with a history of difficulty with donating blood or difficulty in accessibility of veins.
- •The subjects who have donated (1 unit 350 ml / 450 ml) blood within 90 days prior to receiving the first dose of study medication.
- •The subjects who have a positive hepatitis screen (includes subtypes A, B, C & E).
- •The subjects who have a positive test result for HIV antibody and / or syphilis (RPR/VDRL).
- •The subject who receives an investigational product, or has participated in a drug research study within a period of 90 days prior to the first dose of the study medication administration.
- •Female volunteers demonstrating a positive pregnancy screen.
- •Female volunteers who are currently breast-feeding.
- •Female volunteers not willing to use contraception during the study.
研究组 & 干预措施
Eszopiclone Tablets
Experimental
Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
干预措施: Eszopiclone Tablets 3 mg (Drug)
Lunesta
Active Comparator
Lunesta Tablets 3 mg of Sepracor Inc.
干预措施: Eszopiclone Tablets 3 mg (Drug)
结局指标
主要结局
Area under curve
时间窗: 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 24.0, 36.0 and 48.0 hours post dose.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed ConditionsHealthyNCT02322658Dr. Reddy's Laboratories Limited46
已完成
1 期
Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting ConditionsHealthyNCT03706300Dr. Reddy's Laboratories Limited80
已完成
1 期
Bioequivalence Study of Ondansetron Tablets USP 8 mg Under Fasting ConditionFasting StateNCT01578252IPCA Laboratories Ltd.48
已完成
1 期
Bioequivalence Study of Risperidone Tablet 1 mg Under Fed ConditionFedNCT01618760IPCA Laboratories Ltd.48
已完成
1 期
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed ConditionsFedNCT01827878IPCA Laboratories Ltd.48